StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

352 Study Matches

MT2019-01: Adrenoleukodystrophy National Registry Study (ALD) and Biobank

In this protocol, we will enroll pediatric, adolescent and adult patients diagnosed with adrenoleukodystrophy (ALD). These patients will include probands diagnosed by newborn screening and their relatives subsequently diagnosed, as well other patients who are diagnosed with ALD due to other presenting signs and symptoms and subsequently were confirmed to have ALD. We will ask consenting subjects to provide a medical history (with verification via medical records), to participate in a semi-annual health survey and provide consent to collect biospecimens. The overarching goal of this work is to engage with families affected by ALD and to assemble a resource of clinical, medical, and biological data that will allow of to better understand the natural history of ALD, and how this is affected by newborn screening. The initial focus will be on patients within Minnesota, but participation will be open to any family interested in the study, as this will be web-based. This registry and biobank, together with other research conducted in tandem, will possibly provide information describing the natural history of ALD and outcomes with interventions. It is anticipated that the data collected will further our understanding of the natural history of the disease, basic biology of adrenoleukodystrophy, diagnosis and outcomes. Ultimately, this research may lead to new avenues for early diagnosis and development of safer and more effective therapies for ALD.

Ashish Gupta
STUDY00003605
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria Age 0 - 100 ALD patients or family member meeting any of the following criteria: Any patient diagnosed with ALD (confirmed by positive VLCFA testing and/or genetic mutation). Known or presumed mutation with ALD based on pedigree or confirmed mutation in ABCD1 gene Participants living in the United States and territories Exclusion Criteria Patients diagnosed with ALD who lack the capacity to consent/assent AND do not have a designated legally authorized representative or guardian. Patients who have undergone BMT or other cellular therapy . Patients not fluent in English who are unable to consent in-person at the BMT Journey Clinic. Patients who are illiterate Patient determined by the PI or designee to be unlikely to complete required study components (due to language barriers, compliance issues, etc.)
I'm interested
Share via email
See this study on ClinicalTrials.gov

Building Resilience in Adrenoleukodystrophy with Imaging and Neuropsychology (BRAIN)

This study is about a genetic condition called Adrenoleukodystrophy (ALD). The first goal of this study is to understand more about how ALD affects a child’s brain and development in childhood as they take part in medical care and monitoring. This is important to identify the optimal ways to detect and treat manifestations of ALD such as cerebral ALD. The second goal is to learn about how ALD affects caregivers, so that clinicians can offer better support to families in the future. We will also have healthy comparisons to help to learn more about the condition (ALD) being studied, by comparing the information collected to a child without the condition.

Rene Pierpont
Up to 18 years old
This study is also accepting healthy volunteers
STUDY00016246
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 3 to 15 years old
• male
• diagnosis of ALD either at-risk for ALD: patients with genetically or biochemically-diagnosed ALD who currently have no evidence of cerebral disease on MRI and b) Cerebral ALD: boys with the cerebral form of ALD who underwent or are undergoing evaluation or treatment for this condition and have early stage disease
• for healthy volunteers: males between 3 and 15 years old
Exclusion Criteria:

• girls are excluded because this is a genetic disease that only males get
• history of a genetic, neurological, or neurodevelopmental disorder affecting brain development
• history of significant brain insult, infection or injury
Brain & Nervous System, Children's Health, Rare Diseases
Healthy control, children, pediatrics, adolescents
I'm interested
Share via email

National Pediatric Cardiology Quality Improvement Collaborative (NPC-QIC) - A Collaborative Initiative to Improve Care of Children with Complex Congenital Heart Disease (NPC-QIC)

Kavisha Shah
Up to 18 years old
This study is NOT accepting healthy volunteers
STUDY00004329
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• up to 15 months old
• newborns diagnosed with HLHS or other univentricular condition
• intended to undergo Norwood procedure
Children's Health, Heart & Vascular
Hypoplastic Left Heart Syndrome (HLHS)
I'm interested
Share via email
See this study on ClinicalTrials.gov

CONQUER Protocol Number 001: COllaborative, National QUality and Efficacy Registry for Tracking Disease Progression in Systemic Sclerosis (Scleroderma) Patients (CONQUER)

The purpose of this study is to develop a cohort of patients with early scleroderma, and to collect data on clinical outcomes, radiological tests, laboratory tests and to obtain biological specimens for testing.We hope to explore medical care and the impact of SSc on patients' daily lives through various questionnaires that will be collected during study participation. By looking at all of the areas mentioned, we hope to find out information about SSc that will help treat future patients, develop new treatments, and work towards a cure.

Jerry Molitor
18 years and over
This study is NOT accepting healthy volunteers
STUDY00014622
Arthritis & Rheumatic Diseases
Clinics and Surgery Center (CSC)
I'm interested
Share via email

EPI-MINN: Targeting Cognition and Motivation in Coordinated Specialty Care for Early Psychosis: A National Comparison Study

This is a study enrolling patients receiving care at early psychosis specialty coordinated care programs across the United States. Participants will be randomly assigned to one of two groups. The first group will use two mobile apps, computerized brain training and a motivational smart phone app, for a period of 12 weeks. The other group will participate in their regular clinical care. There will be 4 study timepoints: intake, post-training, 6-month follow up, and 12-month follow up. There is also an optional interview about experiences of loneliness.

Sophia Vinogradov
Not specified
This study is NOT accepting healthy volunteers
STUDY00018733
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• aged 15-40 inclusive
• enrolled in an early psychosis coordinated specialty care clinic (PI will determine this)
• in good physical health & stable psychiatric status
• fluent in spoken and written English
• have access to a smart phone (or other mobile device) and computer or tablet
Exclusion Criteria:

• participated in significant cognitive training programs within the last three years
• neurological disorder that may interfere with participation
• substance abuse disorder that would interfere with participation
• risk of suicidal behavior
Brain & Nervous System, Mental Health & Addiction
Psychosis, schizoaffective disorder, schizophrenia
I'm interested
Share via email

MT2023-06: A CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LERIGLITAZONE IN ADULT MALE SUBJECTS WITH CEREBRAL ADRENOLEUKODYSTROPHY (CALYX)

This study has 2 parts: a double-blind period and an open-label extension. In the double-blind period of this study, the study medicine will be compared to a placebo. A placebo is a treatment that looks and tastes exactly like the study medicine but does not contain any active ingredient. In this study, you will receive leriglitazone or placebo. Whether you receive leriglitazone or placebo will be decided randomly (by chance, like flipping a coin). In this study, 1 out of every 2 subjects (50%) will receive leriglitazone and 1 out of every 2 subjects (50%) will receive placebo. To make this study fair, you and the study doctor will not be told which treatment you will receive, this is called “blinding”. In the open-label extension, all subjects will receive leriglitazone.

Troy Lund
18 years and over
This study is NOT accepting healthy volunteers
SITE00001908
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis of progressive cerebral adrenoleukodystrophy (cALD), defined as GdE with brain lesions
• bone marrow transplantation (HSCT) is not recommended patient is not willing to undergo HSCT
• no major cognitive impairment
• see link to clinicaltrials.gov for additional inclusion criteria
Exclusion Criteria:

• or treatment with ex-vivo gene therapy (eli-Cel).
• known type 1 or type 2 diabetes
• see link to clinicaltrials.gov for additional exclusion criteria
Rare Diseases
Clinics and Surgery Center (CSC), CEREBRAL ADRENOLEUKODYSTROPHY, cALD
I'm interested
Share via email
See this study on ClinicalTrials.gov

Muscular Dystrophy Association Neuromuscular Observational Research (MOVR) Data Hub Protocol (#MDACS1)

Multi-Site Registry study

Peter Karachunski
Not specified
This study is NOT accepting healthy volunteers
SITE00000485
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Any person who has a diagnosis of ALS, DMD, BMD, SMA, or any other neuromuscular diseases
Exclusion Criteria:
There are no exclusion criteria
Brain & Nervous System
Muscular Dystrophy, Neuromuscular diseases, Muscular Dystrophy Association (MDA)
I'm interested
Share via email

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

The primary objective for this observational study is to collect general and medical data from children, adolescents, and young adults who had pediatric onset rheumatic disease. This data will be used to evaluate the long-term safety and efficacy of therapeutic agents used to treat these diseases. This information will allow investigators to accurately report and follow changes in current medication use patterns and compare these to proposed standards and current treatment recommendations. The use of a single registry will allow for more analysis of the different therapeutic agents by allowing them to be compared to each other.

Colleen Correll
Not specified
This study is NOT accepting healthy volunteers
1506M74443
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosed with rheumatic disease prior to age 16 years for juvenile idiopathic arthritis (JIA)
• onset prior to age 19 years for all other rheumatic diseases
• younger than 21 years
Arthritis & Rheumatic Diseases, Cancer
juvenile idiopathic arthritis (JIA), pediatric rheumatic disease
I'm interested
Share via email
See this study on ClinicalTrials.gov

The Organ Care System (OCS) Lung Thoracic Organ Perfusion (TOP) Post Approval Study (PAS) Registry - OCS Lung TOP PAS Registry (TOP)

To collect additional real-world safety and effectiveness data for the OCS™ Lung System and to expand the long-term clinical evidence supporting the use of OCS™Lung System in lung transplantation.

Stephen Huddleston
18 years and over
This study is NOT accepting healthy volunteers
STUDY00003837
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• people who received OCS preserved double lung transplants
• OR people who receive a single lung transplant from OCS preserved lung pairs from either standard criteria donors
• AND all donor lungs that were perfused on OCS Lung System
Brain & Nervous System
Clinics and Surgery Center (CSC), Lung Transplant
I'm interested
Share via email
See this study on ClinicalTrials.gov

The (IRAD) International Registry for Acute Aortic Dissection (CCMOCPAAD)

The International Registry of Aortic Dissection (IRAD) was created in 1996 by cardiovascular specialists committed to expanding current knowledge of aortic dissection with the goal of improving patient outcomes. This registry study uses a standardized form to capture data from consecutive patients with aortic dissection at participating hospitals.

Andrew Shaffer
18 years and over
This study is NOT accepting healthy volunteers
1111M06641
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 18 to 80 years of age
• clinical diagnosis of acute aortic dissection
• Type A dissection
• Type B dissection
• Retrograde type B dissection
Exclusion Criteria:

• Aortic aneurysm
• Myocardial infarction
• Cerebral accident
• Active infection
Heart & Vascular
Aortic Dissection
I'm interested
Share via email
See this study on ClinicalTrials.gov

CMRR Healthy Participant Registry

The purpose of this Health Participant Registry is to collect the names, contact information and answers to safety screening questions that assist in the determination of magnetic resonance (MR) compatibility of individuals who have expressed interest in MR research.

Jeramy Kulesa
18 years and over
This study is also accepting healthy volunteers
00015977
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 18 years old
• English speaking
• able to have a MRI scan, must complete assessment
Exclusion Criteria:

• women who are pregnant
Imaging, MRI
Visit study website
I'm interested
Share via email

An Observational Registry of Abatacept in Patients with Juvenile Idiopathic Arthritis (BMS Protocol IM101240)

The objective of this study is to create an international registry with long-term follow-up to characterize and evaluate the safety of abatacept in juvenile idiopathic arthritis (JIA). The primary objective of the JIA registry is to describe the long-term safety of abatacept treatment for JIA by quantifying the incidence rates of serious infections, autoimmune disorders, and malignancies.

Colleen Correll
Up to 18 years old
This study is NOT accepting healthy volunteers
1403M48721
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• less than 18 years of age (unless currently or previously enrolled in an abatacept clinical trial and received abatacept)
• diagnosis of Juvenile Idiopathic Arthritis (JIA)
• currently receiving abatacept per treating physician's decision or received abatacept in a clinical trial
Exclusion Criteria:

• pregnant or breast feeding
• history of cancer unless cancer free for at least 5 years
• any serious acute or chronic medical condition other than JIA
• history of frequently missing clinic appointments
Arthritis & Rheumatic Diseases, Children's Health
Abatacept, Juvenile Idiopathic Arthritis
I'm interested
Share via email
See this study on ClinicalTrials.gov

ELEVATE, a global observational longitudinal prospective registry of patients with acute hepatic porphyria (AHP) (ELEVATE)

This is a global, multicenter, prospective, observational, longitudinal registry conducted to characterize the natural history and real-world clinical management of patients diagnosed with AHP. This protocol will not recommend the use of any specific treatments, visits, or procedures. No medication is provided as part of registry participation.

Gregory Vercellotti
12 years and over
This study is NOT accepting healthy volunteers
SITE00001194
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Documented diagnosis of AHP, per physician's determination
Exclusion Criteria:
Currently enrolled in a clinical trial for any investigational agent
Digestive & Liver Health, Rare Diseases
Clinics and Surgery Center (CSC)
I'm interested
Share via email
See this study on ClinicalTrials.gov

Improving Diagnosis and Treatment in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

This is a multi-center, prospective, observational cohort registry study looking at kids and their relatives with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).

Bradley Clark
Not specified
This study is NOT accepting healthy volunteers
STUDY00011733
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• anyone diagnosed with CPVT before 19 years of age.
Exclusion Criteria:

• significant medical history that isn't related to CPVT
Rare Diseases, Heart & Vascular
CPVT, arrhythmia, ventricular tachycardia
I'm interested
Share via email

Pulmonary Hypertension Association Registry (PHAR) (PHAR)

The PHAR is a multicenter, prospective registry of newly evaluated patients at PHCCs in the United States who have either PAH or CTEPH. The goals of the PHAR include 1) measuring and improving quality of care (including assessing differences in adherence to evidence-based guidelines and establishing benchmarks for health outcomes), 2) determining the clinical effectiveness, comparative effectiveness, and cost effectiveness of treatment approaches, 3) understanding risk factors for outcomes and regional/center differences, and 4) facilitating funded clinical trials of new therapies and collaboration with the PAH community at large, including providers, patients, and their caregivers.

Thenappan Thenappan
Not specified
This study is NOT accepting healthy volunteers
SITE00000044
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis of Pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), or pediatric PH due to developmental lung disease
• within 6 months of first outpatient visit for care
Exclusion Criteria:

• diagnosis of pulmonary hypertension due to other causes/factors
Breathing, Lung & Sleep Health
Clinics and Surgery Center (CSC), Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertensi, Pulmonary Hypertension
I'm interested
Share via email
See this study on ClinicalTrials.gov

Corrona Inflammatory Bowel Disease (IBD) Registry

This is a prospective, non-interventional, research study for patients with IBD under the care of a certified gastroenterologist. The primary objective for this registry is to prospectively study the natural history of IBD, the prevalence and incidence of comorbidities, targeted adverse events, and more, via questionnaires.

Eugenia Shmidt
18 years and over
This study is NOT accepting healthy volunteers
STUDY00007736
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 18 years old
• Diagnosis of one of the following by a gastroenterologist: Crohn's disease or Ulcerative colitis (UC)
• users of an approved biologic drug or JAK inhibitor (Tofacitinib) for the treatment of UC or Crohn's disease
Exclusion Criteria:

• Participating in or planning to participate in a clinical trial studying new medications for Crohn's disease or Ulcerative colitis
Digestive & Liver Health
Clinics and Surgery Center (CSC), Crohn's disease, Ulcerative colitis
I'm interested
Share via email
See this study on ClinicalTrials.gov

Global Patient Registry of Inherited Retinal Diseases

The purpose of this research study is to collect timely and relevant data that will support the evolving research needs of the Inherited Retinal Disease community (IRD), in order to provide insights that can be used to improve patient management, and to inform development of future treatments. No visits, assessments, or procedures are mandated, and follow-up will be captured as part of your standard of care. The planned length of registry is of 8 years with a potential to extend the duration as needs evolve.

Sandra Montezuma
Not specified
SITE00001950
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 3 years old
• documented genetic diagnosis of X-linked retinitis pigmentosa (XLRP) or Achromatopsia (ACHM) with any signs or symptoms of disease
• Caregiver participants must be at least 18 years old and identified by the participant as the primary care giver
Exclusion Criteria:

• received a treatment in an Inherited Retinal Disease (IRD) related interventional trial, or is being screened for an IIRD-related interventional trial
• Caregiver participant has an IRD and has visual impairment
Children's Health, Vision & Eyes
I'm interested
Share via email

Focus in NeuroDevelopment (FIND) Network: A Statewide Network for Research in Neurodevelopment

The purpose of this research project is to develop a registry and database of families with neurodevelopmental disorders.

Suma Jacob
Not specified
This study is also accepting healthy volunteers
1306M35301
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• All ages
• All individuals with disabilities and families within the neurodevelopmental disorder community
• Also looking for clinicians, educators, and professionals in the field
Children's Health, Mental Health & Addiction
autism, OCD, ADHD, tic disorders, neurodevelopment, community outreach
I'm interested
Share via email

DegenPRO: A multicenter prospective registry for the management of degenerative spine disorders

This is an observational registry database for adult patients diagnosed with degenerative spine disorders, which aims to add information to the understanding of the disease management of this spine diseases. By creating this registry, a more complete picture of degenerative spine disorders - including treatment practices - will be established, by collecting information about the health status of patients across several hospitals in several countries. Research of this kind will help future patients by providing doctors with information about degenerative spine disorders, and about patients' treatment outcomes. Data from this registry may be used to generate descriptive statistics on demographics, and clinical characteristics, including co-morbidities, treatment patterns and adverse outcomes (resulting from treatment or disease), as well as patients' quality of life measurements. Condition: Patients with a degenerative spine disorder Intervention/procedure investigated: No specific treatment required. Study design: Prospective case series

Christopher Martin
18 years and over
STUDY00000102
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patient aged 18 years or older Patient diagnosed with a degenerative spine disorder who receives treatment for the degenerative spine disorder Patient capable of understanding the content of the patient information / Informed Consent Form Patient willing and able to participate in the registry Patient who has agreed to participate in the registry by providing consent according to the applicable local law and the declaration of Helsinki
Exclusion Criteria:
None
Clinics and Surgery Center (CSC)
I'm interested
Share via email
See this study on ClinicalTrials.gov

Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry (IPF/ILD-PRO)

Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life of IPF participants, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) established at the enrolling centers. In addition, blood samples will be collected and banked for future research projects.

Hyun Kim
18 years and over
This study is NOT accepting healthy volunteers
1408M52921
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 30 years old
• new diagnosis of Idiopathic Pulmonary Fibrosis (IPF) -diagnosis of a non-IPF Interstitial Lung Disease (ILD) of any duration, including, but not limited to Idiopathic Non-Specific Interstitial, Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis
Exclusion Criteria:

• Cancer, treated or untreated, other than skin or early stage prostate cancer, within the past 5 years
• currently waiting for lung transplantation
• currently enrolled in a clinical trial
Respiratory System
Clinics and Surgery Center (CSC), Idiopathic Pulmonary Fibrosis (IPF) Interstitial Lung Disease
I'm interested
Share via email
See this study on ClinicalTrials.gov

Cardiac Sarcoidosis Consortium

This is a registry study. The Cardiac Sarcoidosis Consortium (CSC) is an international, multicenter partnership among physicians and allied professionals at major medical centers with the unifying purpose to learn more about cardiac sarcoidosis through collaborative research.

Henri Roukoz
18 years and over
This study is NOT accepting healthy volunteers
1209M20465
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• People who have been diagnosed with Cardiac sarcoidosis (CS)
• History of ventricular tachycardia or fibrillation
• Ventricular arrhythmias treated medically or with an implanted device
Heart & Vascular
Ventricular Tachycardia, Cardiac sarcoidosis, ablation, cardiac ablation, Clinics and Surgery Center (CSC)
I'm interested
Share via email

COG APEC14B1 The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study Additional Title: EVERYCHILD (APEC14B1) PCR - COG Foundation

This research trial studies the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

Emily Greengard
Not specified
This study is NOT accepting healthy volunteers
SITE00000151
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• must be =< 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network [NCTN]) therapeutic study, for which there is a higher upper age limit
• patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations
• enrollment must occur within 6 months of initial disease presentation OR within 6 months of refractory disease, disease progression, disease recurrence, second or secondary malignancy
• see link to clinicaltrials.gov for additional inclusion criteria
Cancer
childhood cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov

ALX-HPP-501: An Observational,Longitudinal Prospective, Long-term Registry of Patients with Hypophosphatasia

This is a long-term registry is designed to collect data on hypophosphatasia (HPP) to better understand the condition and learn more about the disease, how patients feel about living with HPP and effect of HPP on the patients wellbeing and health. The study will look at participant’s medical records and health questionnaires about the health status of patients. This study collects observational data from clinical care and does not involve any treatment for HPP or administration of medication for HPP.

Kyriakie Sarafoglou
Not specified
This study is NOT accepting healthy volunteers
STUDY00004936
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• confirmed diagnosis of HPP.
• documented alkaline phosphatase (ALP) activity below the lower limit of normal for age and sex, or a documented ALPL gene mutation.
• able to read and speak English
Exclusion Criteria:

• currently participating in an Alexion-sponsored clinical trial
Rare Diseases
HPP, Hypophosphatasia
I'm interested
Share via email
See this study on ClinicalTrials.gov

Impact of Inflammatory Bowel Disease and IBD-related Surgery on Female Fertility: A Prospective Registry

This is a prospective questionnaire study that will examine the impact of IBD and its surgical treatments on fertility in women with IBD of reproductive age (18-45). Women with IBD who are attempting to get pregnant within the next year will answer questionnaires about their general, surgical and reproductive health, conception history and sexual partner information. This will help identify risk factors predictive of fertility outcomes and early fetal loss, determine time to conception, and assess efficacy of fertility services including in vitro fertilization.

Eugenia Shmidt
18 years and over
This study is NOT accepting healthy volunteers
STUDY00003958
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age 18-45 years
• diagnosis of inflammatory bowel disease (IBD)
• not currently pregnant or trying to get pregnant
• desire to become pregnant within the next 12 months (may become pregnant while in the study)
Exclusion Criteria:

• prior pelvic surgery, including surgery of the cervix, ovary, uterus or fallopian tubes
• known female sterility
• known male infertility factors in partner
Digestive & Liver Health, Women's Health
Fertility, IBD, Inflammatory Bowel Disease
I'm interested
Share via email

Pfizer Registry of Outcomes in Growth hormone RESearch (PROGRES): A multi country, non-interventional prospective cohort study among patients with human growth hormone (hGH) treatments under routine clinical care

The purpose of this study is to learn more about the safety and effectiveness of human growth hormone treatments, in routine practice.

Brad Miller, MD, PhD
Not specified
This study is NOT accepting healthy volunteers
STUDY00016116
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• prescribed human growth hormone (hGH) to treat growth hormone deficiency (GHD)
Exclusion Criteria:

• participation in any interventional clinical trials
Rare Diseases
GHD, Growth Hormone Deficiency, hGH, Human Growth Hormone
I'm interested
Share via email

COG AGCT1531 - A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

This partially randomized phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Emily Greengard
Not specified
This study is NOT accepting healthy volunteers
SITE00000295
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• able to fluently speak and read English
• has received prior cisplatin- or carboplatin-based chemotherapy regimen for malignancy including diagnoses other than germ cell tumor
• see link to clinicaltrials.gov for detailed inclusion criteria
Exclusion Criteria:

• patients with significant, pre-existing co-morbid respiratory disease that contraindicate the use of bleomycin are ineligible for the standard risk arms of the trial
• female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs
• lactating females who plan to breastfeed their infants
• there are additional exclusion criteria (study staff will review)
Cancer
Germ Cell Tumor, Malignant Germ Cell Tumor
I'm interested
Share via email
See this study on ClinicalTrials.gov

The DART Study

We are interested in learning more about how Transcranial Magnetic Stimulation (TMS) and ketamine affect depressive symptoms. We are most interested in learning how anhedonia (lacking pleasure in life) is changed by these treatments. Patients who have been diagnosed with treatment-resistant depression (TRD) and who are also scheduled to receive ketamine or Transcranial Magnetic Stimulation (TMS) are being recruited for this study. We are looking to enroll a second group of participants into a healthy control group who have not been diagnosed with a psychiatric disorder. This group will have a single 60 minute visit in which computer tasks and surveys will be completed while wearing an electroencephalogram (EEG) head cap to record brain activity.

Alexander Herman
18 years and over
This study is also accepting healthy volunteers
STUDY00013617
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• criteria for healthy volunteers: age 18 or older and able to read English
Exclusion Criteria:

• diagnosis or history of depression, bipolar disorder, Generalized Anxiety Disorder, or other psychiatric conditions.
Mental Health & Addiction
Depression, EEG, TMS, Treatment Resistant Depression
I'm interested
Share via email

Liver Collection Study

This is a study of individuals older than 18, undergoing abdominal procedures in which the liver is accessible, and are amenable to liver samples being collected during their surgical procedure, with the option to participate in a specialized scan that can provide information on liver health, stiffness, and fat content. This study is trying to figure out how senescent (aging) cells in the liver are related to an individual's health status and better understand the association between these cells and different metabolic diseases.

Sayeed Ikramuddin
18 years and over
This study is NOT accepting healthy volunteers
STUDY00013764
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Age 18 years or older
• Undergoing abdominal surgical procedure with general anesthesia
Exclusion Criteria:

• Pregnancy or nursing
• Physician may exclude
Diabetes & Endocrine, Digestive & Liver Health, Prevention & Wellness
abdominal surgery, liver biopsy
I'm interested
Share via email

Chilled Platelet Study (CHIPS)

The purpose of this research study is to compare the transfusion of cold-stored (refrigerated) platelets to standard room temperature stored platelets. The goal of the trial is to determine whether platelets stored cold are similar or better at stopping bleeding compared to platelets stored at room temperature and, if so, to determine the maximum duration of cold storage that maintains a similar effect on bleeding

Claudia Cohn
29 days to 84 years old
SITE00001231
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age greater than 28 days and less than 85 years Planned complex cardiac surgery with planned use of cardiopulmonary bypass
Exclusion Criteria:
Expected order for washed or volume reduced platelets Patient with known anti-platelet antibodies Platelet transfusion refractoriness due to anti-HLA antibodies Known or suspected pregnancy Previously randomized in this study Conscious objection or unwillingness to receive blood products Known IgA deficiency Known congenital platelet disorder Known congenital bleeding disorder Planned post-operative extracorporeal membrane oxygenation (ECMO), ventricular assist device (VAD), and/or continuous renal replacement therapy (CRRT)/ hemodialysis Patients intended to receive whole blood either intra-operative or post-operative for bleeding Platelet transfusion (of any type) within 24 hours prior to the date of surgery Pre-operative thrombocytopenia, defined as platelet count <75x10(9)/L, based on the most recent labs completed within 72 hours prior to the date of surgery.
I'm interested
Share via email
See this study on ClinicalTrials.gov

Ten Thousand Families Study

The purpose of this study is to study the evolution of early life risk factors that may lead to cancer and other conditions. This is a prospective cohort study of families who reside in Minnesota.

Jen Poynter
Not specified
This study is also accepting healthy volunteers
STUDY00000877
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 1st Participant: 18+ living in MN
• Other family members: All ages and must live in MN, ND, SD, IA, or WI
• Participants ages 0-17 must have a parent consent to their participation and assist with study activities
Exclusion Criteria:

• Unwilling or unable to provide DNA and blood sample
• Does not have at least 1 living family member in MN IA, ND, SD, or WI
Cancer, Microbiota, Prevention & Wellness
Minnesota, PFAS, environment, exposures, family, genetics, glyphosate, lifestyle, radon, 10KFS
Visit study website
I'm interested
Share via email